Soluble CD30 Levels in Recipients Undergoing Heart Transplantation Do Not Predict Post-transplant Outcome

Journal of Heart and Lung Transplantation

Volumn 28, Issue 11, 2009, Pages 1206-1210

  Ypsilantis, Efthymios ^a   Key, Timothy ^b   Bradley, J Andrew ^a   Morgan, C Helen ^b   Tsui, Stephen ^c   Parameshwar, Jayan ^c   Taylor, Craig J ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD30 ANTIGEN; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HEART ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD30; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEART DISEASES; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350050547     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.05.041     Document Type: Article

References (28)

1. Horie R., and Watanabe T. CD30: expression and function in health and disease. Sem Immunol 10 (1998) 457-470
2. Rossi F., Degan M., Mazzocut-Zecchin L., et al. CD30L up-regulates CD30 and IL-4 expression by T cells. FEBS Lett 508 (2001) 418-422
3. Dai Z., Li Q., Wang Y., et al. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest 113 (2004) 310-317
4. Kennedy M., Willis C., and Armitage R. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 118 (2006) 143-152
5. Pelzl S., Opelz G., Wiesel M., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 73 (2002) 3-6
6. Süsal C., Pelzl S., Döhler B., et al. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13 (2002) 1650-1656
7. Cinti P., Pretagostini R., Arpino A., et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 79 (2005) 1154-1156
8. Rajakariar R., Jivanji N., Varagunam M., et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 5 (2005) 1922-1925
9. Iv R., He Q., Wang H.P., et al. High serum level of the soluble CD30 identifies Chinese kidney transplant recipients at high risk of unfavourable outcome. Transplant Proc 40 (2008) 3375-3380
10. Kim M.S., Kim H.J., Kim S.I., et al. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation. Transplantation 82 (2006) 1602-1605
11. Heinemann F.M., Rebmann V., Witzke O., et al. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 83 (2007) 706-711
12. Slavcev A., Honsova E., Lodererova A., et al. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft. Transplant Immunol 18 (2007) 22-27
13. Altermann W., Schlaf G., Rothhoff A., et al. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?. Nephrol Dial Transplant 22 (2007) 2795-2799
14. Kovac J., Arnol M., Vidan-Jeras B., et al. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation?. Transplant Proc 40 (2008) 1357-1361
15. Frisaldi E., Conca R., Magistroni P., et al. Prognostic values of soluble CD30 and CD30 gene polymorphisms in heart transplantation. Transplantation 81 (2006) 1153-1156
16. Spiridon C., Hunt J., Mack M., et al. Evaluation of soluble CD30 as an immunologic marker in heart recipients. Transplant Proc 38 (2006) 3689-3691
17. Nikaein A., Spiridon C., Hunt J., et al. Pre-transplant level of soluble CD30 is associated with infection after heart transplantation. Clin Transplant 21 (2007) 744-747
18. Itescu S., and John R. Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications. Ann Thorac Surg 75 suppl (2003) S58-S65
19. Pelzl S., Opelz G., Daniel V., et al. Evaluation of post-transplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 75 (2003) 421-423
20. Süsal C., Pelzl S., Simon T., et al. Advances in pre- and post-transplant immunologic testing in kidney transplantation. Transplant Proc 36 (2004) 29-34
21. Sengul S., Keven K., Gormez U., et al. Identification of patients at risk of acute rejection by pre-transplantation and post-transplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 81 (2006) 1216-1219
22. Dong W., Shunliang Y., Weizhen W., et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transplant Immunol 16 (2006) 41-45
23. Langan L.L., Park L.P., Hughes T.L., et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 7 (2007) 847-856
24. Wang D., Wu G.J., Wu W.Z., et al. Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transplant Immunol 17 (2007) 278-282
25. López-Hoyos M., San Segundo D., Benito M.J., et al. Association between serum soluble CD30 and serum creatinine before and after renal transplantation. Transplant Proc 40 (2008) 2903-2905
26. Weimer R., Süsal C., Yildiz S., et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 6 (2006) 1865-1874
27. Kwakkel-van Erp J.M., Otten H.G., Paantjens A.W., et al. Soluble CD30 measured after lung transplantation does not predict bronchiolitis obliterans syndrome in a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen. J Heart Lung Transplant 27 (2008) 1172-1175
28. Golocheikine A.S., Saini D., Ramachandran S., et al. Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation. Transplant Immunol 18 (2008) 260-263